Related Experiment Video
Updated: Jan 22, 2026

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
Published on: October 2, 2014
Who Benefits from Treatment of Primary Hyperparathyroidism?
Catherine Y Zhu1, Dalena T Nguyen1, Michael W Yeh1
1Section of Endocrine Surgery, Department of Surgery, UCLA David Geffen School of Medicine, 10833 Le Conte Avenue, CHS 72-182, Los Angeles, CA 90095, USA.
Abstract:
Parathyroidectomy (PTx) is the only definitive treatment for primary hyperparathyroidism (PHPT), but is commonly underutilized. Most patients are medically observed, whereas approximately 30% of patients are treated operatively. PTx is a low-risk surgical procedure and the most cost-effective treatment option. An international consensus statement was published in 1990 to guide clinicians in the management of patients with PHPT, particularly those with asymptomatic disease. Most patients with PHPT and low perioperative risk benefit from surgical treatment, regardless of whether they meet consensus criteria, due to fracture risk reduction, health-related quality-of-life improvements, and prevention or mitigation of disease progression.
Related Concept Videos
Benefits of Self-Esteem
Primary Active Transport
Primary and Secondary Growth in Roots and Shoots
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Alzheimer's Disease: Treatment
Primary Distribution

